

Tarpeyo® (budesonide) – Updated indication, accelerated approval converted to full approval

- On December 20, 2023, <u>Calliditas Therapeutics announced</u> the full FDA approval of <u>Tarpeyo</u> (<u>budesonide</u>), to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
 - Tarpeyo was previously approved under accelerated approval, to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-tocreatinine ratio (UPCR) ≥ 1.5 g/g.
- The full approval of Tarpeyo for the updated indication was based on NeflgArd, a randomized, double-blind, 2-part study in 364 adults with IgAN who were on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy. Patients were randomized to receive Tarpeyo or placebo. The primary endpoint for Part B of the study (final analysis) was a time-weighted average of the log ratio of estimated glomerular filtration rate (eGFR) at each time point over 2 years relative to baseline.
 - The study met the prespecified Part B primary endpoint (p < 0.0001). The favorable effect of Tarpeyo on eGFR was seen by month 3 (the earliest assessment) and did not appear to increase in magnitude over two years. At year 2, there was a 5.9 mL/min/1.73 m² difference in the mean change from baseline in eGFR between Tarpeyo and placebo (95% CI: 3.3, 8.5 mL/min/1.73 m²; p < 0.0001).</p>
- The recommended treatment duration with Tarpeyo is 9 months, with a dosage of 16 mg administered orally once daily. When discontinuing therapy, the dosage should be reduced to 8 mg once daily for the last 2 weeks of therapy.
- Safety and efficacy of treatment with subsequent courses of Tarpeyo have not been established.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.